Apathy is Associated With Lower Inferior Temporal Cortical Thickness in Mild Cognitive Impairment and Normal Elderly Individuals
Publication: The Journal of Neuropsychiatry and Clinical Neurosciences
Abstract
Apathy is a common neuropsychiatric symptom in Alzheimer’s disease dementia and amnestic mild cognitive impairment and is associated with cortical atrophy in Alzheimer’s disease dementia. This study investigated possible correlations between apathy and cortical atrophy in 47 individuals with mild cognitive impairment and 19 clinically normal elderly. Backward elimination multivariate linear regression was used to evaluate the cross-sectional relationship between scores on the Apathy Evaluation Scale and thickness of several cortical regions and covariates. Lower inferior temporal cortical thickness was predictive of greater apathy. Greater anterior cingulate cortical thickness was also predictive of greater apathy, suggesting an underlying reactive process.
Apathy, characterized by social withdrawal and loss of goal oriented behavior, interest, and motivation, is the neuropsychiatric symptom most commonly associated with Alzheimer’s disease (AD) dementia and one of the symptoms most commonly associated with amnestic mild cognitive impairment (MCI).1–3 Apathy is also associated with functional impairment and disease progression.4–7 Apathy has been shown to most consistently correlate with atrophy of the medial frontal cortex in AD dementia; however, the precise region of apathy-associated cortical atrophy has varied between studies.8–10
Cortical thinning has been detected in clinically normal (CN) elderly individuals with greater amyloid burden seen on Pittsburgh Compound B (PiB) positron emission tomography (PET)11,12 and apathy has been associated with increased cortical amyloid burden in MCI.13 Accordingly, cortical thinning has been detected in CN individuals with low cerebrospinal fluid amyloid-β1–42.14 Therefore, atrophy associated with apathy in AD dementia patients may begin during MCI and possibly even in CN individuals at risk for AD. Although apathy is known to manifest at the stage of MCI, which can represent prodromal AD, the possibility of apathy-associated atrophy in CN individuals possibly at the preclinical stage of AD remains relatively unexplored. In a study of mild AD dementia, MCI, and CN individuals from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), Donovan et al. found that reduced baseline inferior temporal cortical thickness was predictive of greater apathy over time across all diagnoses.15 This reduced thickness may have indicated cortical atrophy associated with AD pathology, atrophy associated with normal aging, or innately reduced inferior temporal cortical thickness which could predispose toward the development of apathy. If AD-induced, apathy-associated cortical atrophy is found in the preclinical or prodromal stages of disease, it may be a useful biomarker for clinical trials involving the earliest stages of AD. Furthermore, not all cases of MCI advance to AD dementia.16 If detection of apathy with regionally specific atrophy in MCI or CN individuals is predictive of such progression, these markers may be useful for earlier and more accurate diagnosis of AD.
In this study, we set out to investigate the possibility of apathy-associated regionally specific cortical atrophy in MCI and CN individuals cross-sectionally. To evaluate apathy, we employed the clinician-rated Apathy Evaluation Scale (AES-C) (made up of 18 items),17 a comprehensive method of quantifying many aspects of apathy. MRI was employed to assess regional cortical thickness. We hypothesized that greater apathy in MCI and CN individuals would be associated with atrophy of medial frontal regions, as has been demonstrated previously in AD dementia,8,10 and inferior temporal atrophy as recently seen in individuals with milder cognitive impairment.15 Detection of such apathy-associated cortical atrophy in MCI or CN individuals may provide opportunities for earlier AD diagnosis and enriched clinical trial designs.
Methods
Subjects
Sixty six subjects (47 MCI, 19 CN) ages 53 to 86 were recruited from the clinic and community to participate in an investigator-initiated imaging study at the Brigham and Women’s Hospital and Massachusetts General Hospital Center for Alzheimer Research and Treatment where they underwent clinical assessments and MRI scans. Experienced clinicians diagnosed subjects as either MCI or CN using Clinical Dementia Rating (CDR), Global and Memory Box scores, the Mini-Mental State Examination (MMSE), and scores on the Logical Memory IIa (delayed recall) of the Revised Wechsler Memory Scale. Subjects were medically stable and did not have significant cofounding neurological conditions, substance or alcohol abuse within the past 2 years, or primary psychiatric diagnoses (e.g., major depressive disorder) within the past 2 years. Subjects had a Modified Hachinski Ischemic Score≤418 and a Geriatric Depression Scale (long form) ≤ 10.19 The study was approved by the local Institutional Review Board, and informed consent was obtained from all subjects before any of the study procedures were carried out.
Clinical Assessments
Clinician-Rated Apathy Evaluation Scale (AES-C)17: Apathy was quantified using the AES-C, consisting of 18 items relating to apathy scored on a four-point Likert-type scale based on the clinician’s impression of the subject. The score range for the complete AES-C is 18 to 72, with a lower score indicating greater apathy.
The Rey Auditory Verbal Learning Test (RAVLT) total learning was used to assess memory; the Wechsler Adult Intelligence Scale-Revised Digit Symbol test was used to assess aspects of executive function, including processing speed, visual scanning, and working memory; and the American National Adult Reading Test (AMNART) IQ was used as an estimate of premorbid verbal IQ, a proxy of cognitive reserve.
MRI Data
MRI scans were conducted with a Siemens Trio 3T scanner (Siemens Medical Systems, Erlangen, Germany). High-resolution T1-weighted structural images were acquired using a 3D Magnetization Prepared Rapid Acquisition Gradient Echo (MP-RAGE) sequence with the following acquisition parameters: repetition time=2300ms; echo time=2.98ms; inversion time=900 ms; flip angle=9°; voxel size=1.0×1.0×1.2 mm. Cortical thickness of regions-of-interest (ROI) was measured using FreeSurfer Version 5.1 (http://surfer.nmr.mgh.harvard.edu/). A priori ROI included 1) inferior temporal cortex; 2) rostral anterior cingulate cortex; 3) medial orbitofrontal cortex; and 4) supramarginal cortex. We chose to focus on cortical regions rather than deep subcortical structures. The anterior cingulate and medial orbitofrontal cortices have been associated with apathy across imaging modalities in AD dementia20–25; the inferior temporal cortex has been associated with apathy in a similar early AD sample in ADNI15; and the supramarginal cortex was chosen because it has been associated with early AD though less consistently with apathy.26,27 Cortical thickness for each ROI was averaged across both hemispheres. A single individual (AMW) blinded to the clinical status of the subjects verified ROI parcellations and performed minor edits. The mean interval between MRI acquisition and clinical assessment was 35±36 days.
Statistical Analyses
All analyses were carried out using SAS Version 9.2 (SAS Institute, Cary, N.C.) and SPSS Version 20 (IBM, Armonk, N.Y.). Associations among diagnostic groups, subject demographics, and characteristics were evaluated using the χ2 test for categorical variables and two-tailed independent-samples t tests for continuous variables; if Levene’s test indicated unequal variances, two-tailed Welch’s t test was performed instead. Variances of demographic and characteristic data were assessed for normality using One-Sample Kolmogrov-Smirnov tests and frequency histograms; independent-samples Mann-Whitney U tests were used if variables demonstrated nonnormal distributions. Associations between AES-C score and subject demographics and characteristics were evaluated using independent-sample t tests for categorical variables and Pearson correlations for continuous variables.
A general linear regression model with backward elimination (p <0.05 retention requirement) was used to evaluate the cross-sectional relationship of the dependent variable, apathy (measured by AES-C score), with the following predictors: four a priori MRI ROI, diagnosis (MCI or CN), age, AMNART IQ, Digit Symbol score, and RAVLT total learning. Partial regression coefficient estimates (β) and confidence intervals (CI) and significance test results (p values) were reported for each predictor retained after backward elimination. Percent variance accounted for in the dependent variable by the model as a whole (R2) was also reported. The distributions of data points from residuals of the final model were assessed graphically for normality and homoscedasticity to ensure consistency with the model’s assumptions.
Results
Demographics and characteristics for all subjects and each diagnostic group are displayed in Table 1. Compared with CN subjects, MCI subjects demonstrated significantly lower MMSE scores, Digit Symbol scores, RAVLT total learning scores, and AES-C scores (indicating greater apathy), and significantly higher CDR sum of boxes scores. The MCI group also had a higher percentage of males than the CN group. Lower AES-C score (greater apathy) was associated with lower MMSE (r=0.29, p=0.02), Digit Symbol (r=0.34, p=0.007), and RAVLT total learning scores (r=0.39, p=0.001), and with higher CDR sum of boxes scores (r=−0.583, p<0.001).
| Characteristic | All Subjects | MCI | CN | Significant Differences Between MCI Versus CN |
|---|---|---|---|---|
| N | 66 | 47 | 19 | — |
| Age (years) | 74.6±7.7 (53–86) | 74.5±8.4 (53–86) | 75.1±5.9 (63–84) | — |
| Sex (% male) | 59.1 | 74.5 | 21.1 | χ2 test=16.0, p<0.001 |
| Education (years) | 17.0±2.5 (12–20) | 17.0±2.4 (12–20) | 17.1±2.9 (12–20) | — |
| AMNART IQ | 122.1±7.1 (100–131) | 121.5±7.6 (100–131) | 123.5±5.3 (111–130) | — |
| MMSE | 28.1±1.8 (24–30) | 27.6±1.8 (24–30) | 29.6±0.7 (28–30) | Mann-Whitney U test, p<0.001 |
| CDR-SB | 1.3±1.1 (0.0–3.5) | 1.7±1.0 (0.5–3.5) | 0.0±0.1 (0–0.5) | Mann-Whitney U test, p<0.001 |
| Digit symbol | 46.7±12.4 (21–71) | 44.3±12.3 (21–69) | 52.4±11.1 (34–71) | t=2.49, p=0.02 |
| RAVLT | 38.3±12.1 (18–71) | 33.2±8.6 (18–55) | 51.1±9.8 (34–71) | t=7.37, p<0.001 |
| AES-C | 63.0±7.6 (39–72) | 61.0±7.7 (39–72) | 68.4±4.1 (55–72) | Welch’s t test, t=4.85, p<0.001 |
a
AES-C: Apathy Evaluation Scale, clinician rated; AMNART IQ: American National Adult Reading Test intelligence quotient; CDR-SB: Clinical Dementia Rating sum of boxes; CN: clinically normal; MCI: amnestic mild cognitive impairment;, MMSE: Mini-Mental State Examination; RAVLT: Rey Auditory Verbal Learning Test total learning.
All values (except for n and sex) represent mean±standard deviation (range).
After backward elimination, the multivariate linear regression model indicated a significant association between lower AES-C scores, representing greater apathy, and lower inferior temporal cortical thickness (p=0.004) and greater anterior cingulate cortical thickness (p=0.04), see Table 2 and Figure 1. Thickness of other cortical ROI was not significantly associated with AES-C score. Other predictors retained in the model included diagnosis, where an MCI diagnosis was more associated with lower AES-C score (greater apathy) than a CN diagnosis (p=0.0007) (R2=0.31, p=0.0001 for model), see Table 2. Of note, there was a moderately strong positive unadjusted univariate correlation between inferior temporal and anterior cingulate cortical thickness (r=0.51, p<0.0001) suggesting possible multicollinearity as an explanation for the unexpected inverse relationship of AES-C score with anterior cingulate cortical thickness seen in the model. However, the unadjusted univariate correlation between anterior cingulate cortical thickness and AES-C score, which does not reach statistical significance (r=−0.12, p=0.37), was negative as it was in the model.
| Model: R2=0.31, p=0.0001 | |||
|---|---|---|---|
| Retained Predictors | β | 95% CI for β | p |
| Inferior temporal cortex | 18.07 | 6.45, 29.70 | 0.004 |
| Anterior cingulate cortex | –10.03 | –19.38, –0.68 | 0.04 |
| Diagnosis of MCI | –6.52 | –10.10, –2.95 | 0.0007 |
a
AES-C: Apathy Evaluation Scale, clinician rated; β: partial regression coefficient estimate; CI: confidence interval; CN: clinically normal; MCI: amnestic mild cognitive impairment; MRI ROI: magnetic resonance imaging region of interest.
Discussion
In this study, we sought to identify regions of lower cortical thickness suggestive of atrophy that are associated with apathy in individuals possibly at the prodromal stage of AD, characterized clinically as MCI, and CN elderly. The results of our study suggest that lower thickness of the inferior temporal cortex is associated with greater apathy in both CN and MCI individuals after adjusting for diagnosis, age, premorbid intelligence, memory performance, and processing speed. Our results also suggest an association between greater anterior cingulate cortical thickness and greater apathy in this population.
Investigational AD treatments at the stage of mild-moderate dementia have failed to demonstrate clinical efficacy. A potential explanation for these negative results is late therapeutic intervention at a stage of the disease at which there is already advanced pathology. For clinical trials to be successful, superior biomarker profiles for earlier diagnosis and intervention may be needed. It is well established that a significant proportion of individuals with MCI is at the prodromal stage of AD,16,28,29 and biomarkers indicative of AD pathology have already been found preceding MCI in CN elderly individuals.11,28,30 Such promising early biomarkers include fibrillar amyloid-β as visualized by PiB PET. However, CN individuals who may or may not develop AD have also been shown to be PiB-positive; therefore, this marker may not be sufficient to predict progression to AD dementia alone.11,30 Other biomarkers are also needed.
Apathy is well-established as the most common neuropsychiatric symptom of AD dementia and one of the most common in MCI.1–3 It is also predictive of impaired instrumental activities of daily living in AD dementia and progression from MCI to AD dementia.5,7,31 Apathy has been shown to correlate with regionally specific cortical changes in AD dementia, including microstructural alterations in white matter anisotropy of the left anterior cingulate cortex,20 reduced metabolism and perfusion of the anterior cingulate cortex21–25 and the orbitofrontal cortex,21–23,25 decreased perfusion of the right temporoparietal cortex,32 and decreased perfusion of the prefrontal cortex and anterior temporal cortex.33 Apathy has also been associated with greater neurofibrillary tangle burden of the anterior cingulate cortex34 in moderate to severe AD dementia and increased cerebrospinal fluid total tau and phospho-tau in mild AD dementia.35
Multiple studies have demonstrated an association between apathy and atrophy of the medial frontal regions in AD dementia. While Apostolova et al. found reduced gray matter thickness of the bilateral anterior cingulate and left medial frontal cortex (supplementary motor area),8 Bruen et al. found cortical thinning of the anterior cingulate cortex bilaterally, frontal cortex bilaterally, head of the left caudate nucleus, and bilateral putamen.9 Tunnard et al. partially corroborated both studies with findings of atrophy in the left caudal anterior cingulate cortex, left lateral orbitofrontal cortex, and left superior and ventrolateral frontal regions.10 Associations between apathy and atrophy of the medial frontal regions have also been found in related neurodegenerative dementias.36 Moreover, associations between apathy and cortical amyloid burden have been detected as early as MCI.13 Since cortical thinning patterns associated with AD have been detected as early as the preclinical stages of AD in PiB-positive CN individuals,11,37 it is plausible to hypothesize that apathy-associated patterns of atrophy may begin at the stage of MCI or earlier.
Our findings regarding lower inferior temporal cortical thickness build on previous studies suggesting a role for lower inferior temporal cortical thickness as a predictor of greater apathy over time and the detection of inferior temporal cortex atrophy in the early stages of MCI.15,27 In a study using ADNI data, Donovan et al. found reduced baseline inferior temporal cortical thickness to be predictive of increasing apathy over time across the AD continuum, including CN, MCI, and mild AD dementia subjects.15 Unlike the current study, this study did not detect a significant cross-sectional association between decreased thickness of the inferior temporal cortex and greater apathy; however, this may be due to the scale used to measure apathy, the Neuropsychiatric Inventory brief questionnaire (NPI-Q), which only features a single item for apathy with a possible score range of 0–3.38 Many other clinical-imaging correlation studies of apathy in AD dementia have used the full NPI scale, which has a wider range of scores (0–12),39 but often was split into a dichotomous variable (present or absent apathy).8–10,25,33 More comprehensive and sensitive measures of apathy, such as the AES employed here (possible score range 18–72), may reveal subtler cross-sectional associations between cortical thickness and apathy in individuals who may be in the early stages of AD. In a separate study using ADNI data, McDonald et al. identified accelerated inferior lateral temporal atrophy starting in the early stages of MCI (CDR sum of boxes 0.5–1.0) and continuing into mild AD dementia.27 Coupled with our findings, these studies suggest that inferior temporal atrophy may occur in individuals in the prodromal stages of AD and that regional atrophy in these stages of disease may be associated with the presence of apathy.
However, our results are cross-sectional rather than longitudinal. Therefore, it is unclear whether the lower inferior temporal cortical thickness associated with apathy is the result of atrophy over time or an innate life-long trait which predisposes to apathy. Furthermore, while most of the subjects in this study are at high risk for developing AD dementia, we did not know which subjects or how many ultimately progressed to AD dementia. Therefore, the association between lower inferior cortical thickness and apathy may or may not be driven by underlying AD pathology. Further studies with PiB PET and longitudinal data are needed.
Despite significant evidence for apathy-associated atrophy of the anterior cingulate cortex in AD dementia,8–10 the lack of an association between lower anterior cingulate cortical thickness and apathy in our subjects may not be entirely surprising. While McDonald et al.’s study of longitudinal cortical atrophy in MCI and AD dementia did detect inferior lateral temporal atrophy in the early stages of MCI, it did not detect atrophy of the anterior cingulate cortex until impairment increased to a CDR sum of boxes score of 1.5–2.5.27 The mean CDR sum of boxes score in MCI subjects in the current study was 1.7 and CN subjects were included as well, potentially reducing the possibility of observing a regional association with anterior cingulate cortex atrophy and apathy. Therefore, greater apathy may be associated with anterior cingulate atrophy only in later stages of the disease than examined by the current study, while inferior temporal atrophy may be associated with greater apathy at earlier stages of AD.
It is difficult to explain the unexpected association between greater apathy and greater anterior cingulate cortical thickness observed in our study. When looking at the univariate unadjusted relationship between apathy and anterior cingulate cortical thickness, the directionality is the same as that found in the multivariate model. This suggests that the weak yet statistically significant relationship between greater anterior cingulate cortical thickness and greater apathy may be a real finding. This finding may suggest a compensatory or inflammatory response to AD pathology in the anterior cingulate cortex which precedes atrophy. Analogous phenomena have been identified in other brain regions. Functional MRI studies have shown a potential compensatory effect at the stage of early MCI with increased hippocampal activity during a memory task, which later reverses to decreased activity at the stage of late MCI.40 The findings of increased anterior cingulate cortical thickness in CN and early MCI subjects and decreased anterior cingulate cortical thickness in mild-moderate AD dementia could be due to a similar compensatory phenomenon. However, this finding is in cortical thickness rather than function. There is some evidence to support a similar phenomenon with cortical thickness measurements in the earliest stages of AD. In an MRI study of early-onset familial AD mutation carriers, cortical thickness of the posterior cingulate, precuneus and parietotemporal association areas were greater in mutation carriers prior to the onset of cognitive impairment than in healthy controls, while thickness of the same areas after symptom onset was significantly less than that found in healthy controls.41 In a separate study, nondemented apolipoprotein E ε4 carriers had greater cortical thickness than noncarriers, but a stronger association between aging and cortical thinning between the ages of 48 and 75 years in cortical areas known to degenerate in AD.42
The current study had several limitations. First, we were limited to observing anatomical features in the brain. Apathy may also correlate with functional, metabolic, or molecular changes in the brains of MCI and CN individuals. Techniques such as resting-state functional MRI, 18F-fluorodeoxyglucose PET, and PiB-PET may be used to investigate such possibilities in future studies. Of note, we recently reported results of a cross-sectional association between apathy and PiB burden but not FDG metabolism in a small sample of MCI subjects.13 These findings need to be extended to CN subjects and have a longitudinal component as well. Furthermore, larger samples are needed to assess the relationship between apathy and regional cortical thickness within PiB-positive individuals who are more likely to have preclinical and prodromal AD than the inclusive group of CN and MCI subjects used in the current study, who could have been PiB-positive or negative. Because of a small sample size, we were limited in the number of ROI that could be chosen for our analyses, and decreased thickness of other cortical regions associated with apathy in early AD may have been missed. Future studies will employ whole-brain exploratory analyses with voxel-based morphometry to test for such regions. Small sample size also limited the number of covariates we could control for in our general linear model. Future larger studies may be able to adjust for additional relevant covariates and also have greater statistical power to detect subtler effects of individual predictors. The cross-sectional nature of this study was another limitation. Our study suggests that decreased inferior temporal cortical thickness is associated with greater apathy cross-sectionally. However, given the lack of longitudinal analysis, it is impossible to determine whether or not the decreased cortical thickness observed here is actually the result of pathology related atrophy or instead inherent to the subjects at baseline, predisposing them to apathy their entire life. Future longitudinal studies with both repeated MRI and clinical assessments will allow for better exploration of this question and will also help determine whether certain regional atrophy patterns predict greater apathy over time and progression of AD.
Conclusions
Our results suggest that lower inferior temporal cortical thickness, likely attributable to atrophy, is associated with greater apathy in MCI and CN elderly individuals. Our results also suggest that greater rostral anterior cingulate cortical thickness may be associated with apathy in early MCI and CN elderly individuals, perhaps as a result of compensatory neuronal changes or inflammatory responses to underlying pathology. These findings were present after accounting for age, premorbid intelligence, diagnostic group, processing speed, and memory performance.
References
1.
Lyketsos CG, Lopez O, Jones B, et al: Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 2002; 288:1475–1483
2.
Mega MS, Cummings JL, Fiorello T, et al: The spectrum of behavioral changes in Alzheimer’s disease. Neurology 1996; 46:130–135
3.
Apostolova LG, Cummings JL: Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature. Dement Geriatr Cogn Disord 2008; 25:115–126
4.
Wadsworth LP, Lorius N, Donovan NJ, et al: Neuropsychiatric symptoms and global functional impairment along the Alzheimer’s continuum. Dement Geriatr Cogn Disord 2012; 34:96–111
5.
Palmer K, Di Iulio F, Varsi AE, et al: Neuropsychiatric predictors of progression from amnestic-mild cognitive impairment to Alzheimer’s disease: the role of depression and apathy. J Alzheimers Dis 2010; 20:175–183
6.
Starkstein SE, Jorge R, Mizrahi R, et al: A prospective longitudinal study of apathy in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2006; 77:8–11
7.
Boyle PA, Malloy PF, Salloway S, et al: Executive dysfunction and apathy predict functional impairment in Alzheimer disease. Am J Geriatr Psychiatry 2003; 11:214–221
8.
Apostolova LG, Akopyan GG, Partiali N, et al: Structural correlates of apathy in Alzheimer’s disease. Dement Geriatr Cogn Disord 2007; 24:91–97
9.
Bruen PD, McGeown WJ, Shanks MF, et al: Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimer’s disease. Brain 2008; 131:2455–2463
10.
Tunnard C, Whitehead D, Hurt C, et al: AddNeuroMed Consortium: Apathy and cortical atrophy in Alzheimer’s disease. Int J Geriatr Psychiatry 2011; 26:741–748
11.
Becker JA, Hedden T, Carmasin J, et al: Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol 2011; 69:1032–1042
12.
Chételat G, Villemagne VL, Bourgeat P, et al: Australian Imaging Biomarkers and Lifestyle Research Group: Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol 2010; 67:317–324
13.
Marshall GA, Donovan NJ, Lorius N, et al: Apathy is associated with increased amyloid burden in mild cognitive impairment. J Neuropsychiatry Clin Neurosci 2013; 25:302–307
14.
Schott JM, Bartlett JW, Fox NC, et al: Alzheimer’s Disease Neuroimaging Initiative Investigators: Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1-42. Ann Neurol 2010; 68:825–834
15.
Donovan NJ, Wadsworth LP, Lorius NL, et al: Alzheimer Disease Neuroimaging Initiative: Regional cortical thinning predicts worsening apathy and hallucinations across the Alzheimer’s disease spectrum. Am J Geriatr Psychiatry 2013; (in press)
16.
Petersen RC, Smith GE, Waring SC, et al: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56:303–308
17.
Marin RS, Biedrzycki RC, Firinciogullari S: Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res 1991; 38:143–162
18.
Rosen WG, Terry RD, Fuld PA, et al: Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980; 7:486–488
19.
Yesavage JA, Brink TL, Rose TL, et al: Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982-1983; 17:37–49
20.
Kim JW, Lee DY, Choo IH, et al: Microstructural alteration of the anterior cingulum is associated with apathy in Alzheimer disease. Am J Geriatr Psychiatry 2011; 19:644–653
21.
Marshall GA, Monserratt L, Harwood D, et al: Positron emission tomography metabolic correlates of apathy in Alzheimer disease. Arch Neurol 2007; 64:1015–1020
22.
Robert PH, Darcourt G, Koulibaly MP, et al: Lack of initiative and interest in Alzheimer’s disease: a single photon emission computed tomography study. Eur J Neurol 2006; 13:729–735
23.
Benoit M, Clairet S, Koulibaly PM, et al: Brain perfusion correlates of the apathy inventory dimensions of Alzheimer’s disease. Int J Geriatr Psychiatry 2004; 19:864–869
24.
Migneco OBM, Benoit M, Koulibaly PM, et al: Perfusion brain SPECT and statistical parametric mapping analysis indicate that apathy is a cingulate syndrome: a study in Alzheimer’s disease and nondemented patients. Neuroimage 2001; 13:896–902
25.
Lanctôt KL, Moosa S, Herrmann N, et al: A SPECT study of apathy in Alzheimer’s disease. Dement Geriatr Cogn Disord 2007; 24:65–72
26.
Dickerson BC, Bakkour A, Salat DH, et al: The cortical signature of Alzheimer’s disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex 2009; 19:497–510
27.
McDonald CR, McEvoy LK, Gharapetian L, et al: Alzheimer’s Disease Neuroimaging Initiative: Regional rates of neocortical atrophy from normal aging to early Alzheimer disease. Neurology 2009; 73:457–465
28.
Tierney MC, Szalai JP, Snow WG, et al: Prediction of probable Alzheimer’s disease in memory-impaired patients: A prospective longitudinal study. Neurology 1996; 46:661–665
29.
Bowen J, Teri L, Kukull W, et al: Progression to dementia in patients with isolated memory loss. Lancet 1997; 349:763–765
30.
Jack CR JrLowe VJ, Weigand SD, et al: Alzheimer’s Disease Neuroimaging Initiative: Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease. Brain 2009; 132:1355–1365
31.
Marshall GA, Rentz DM, Frey MT, et al: Alzheimer’s Disease Neuroimaging Initiative: Executive function and instrumental activities of daily living in mild cognitive impairment and Alzheimer’s disease. Alzheimers Dement 2011; 7:300–308
32.
Ott BR, Noto RB, Fogel BS: Apathy and loss of insight in Alzheimer’s disease: a SPECT imaging study. J Neuropsychiatry Clin Neurosci 1996; 8:41–46
33.
Craig AH, Cummings JL, Fairbanks L, et al: Cerebral blood flow correlates of apathy in Alzheimer disease. Arch Neurol 1996; 53:1116–1120
34.
Marshall GA, Fairbanks LA, Tekin S, et al: Neuropathologic correlates of apathy in Alzheimer’s disease. Dement Geriatr Cogn Disord 2006; 21:144–147
35.
Skogseth R, Mulugeta E, Jones E, et al: Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer’s disease. Dement Geriatr Cogn Disord 2008; 25:559–563
36.
Rosen HJ, Allison SC, Schauer GF, et al: Neuroanatomical correlates of behavioural disorders in dementia. Brain 2005; 128:2612–2625
37.
Chételat G, Villemagne VL, Villain N, et al: AIBL Research Group: Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition. Neurology 2012; 78:477–484
38.
Kaufer DI, Cummings JL, Ketchel P, et al: Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 2000; 12:233–239
39.
Cummings JL, Mega M, Gray K, et al: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44:2308–2314
40.
Celone KA, Calhoun VD, Dickerson BC, et al: Alterations in memory networks in mild cognitive impairment and Alzheimer’s disease: an independent component analysis. J Neurosci 2006; 26:10222–10231
41.
Fortea J, Sala-Llonch R, Bartrés-Faz D, et al: Increased cortical thickness and caudate volume precede atrophy in PSEN1 mutation carriers. J Alzheimers Dis 2010; 22:909–922
42.
Espeseth T, Westlye LT, Fjell AM, et al: Accelerated age-related cortical thinning in healthy carriers of apolipoprotein E epsilon 4. Neurobiol Aging 2008; 29:329–340
Information & Authors
Information
Published In
History
Received: 26 June 2013
Revision received: 9 February 2014
Accepted: 13 February 2014
Published ahead of print: 10 November 2014
Published in print: Winter 2015
Published online: 26 February 2015
Authors
Funding Information
NIH Clinical Center10.13039/100000098: R01 AG027435
NIH Clinical Center10.13039/100000098: K23 AG033634
NIH Clinical Center10.13039/100000098: K24 AG035007
This research was supported by R01 AG027435, K23 AG033634, K24 AG035007, the Rosalinde and Arthur Gilbert Foundation/AFAR New Investigator Awards in Alzheimer’s Disease, the Massachusetts Alzheimer’s Disease Research Center (P50 AG005134), and the Harvard Aging Brain Study (P01 AGO36694, R01 AG037497). Authors have also received research salary support from the Harvard Medical School Scholars in Medicine Office.The authors report no financial relationships with commercial interests.Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBGet Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).